KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their dependence on mutant KRAS. However, analysis of the remaining cell population after long-term Cas9 expression unmasked the occurence of oncogenic KRAS escape variants that were resistant to Cas9-cleavage. In contrast, the use of an adenine base editor to correct oncogenic KRAS mutations progressively depleted the targeted cells without the appearance of escape variants and allowed efficient and simultaneous correction of a cancer-associated TP53 mutation. Oncogenic KRAS and TP53 base editing was possible in patient-derived cancer organoids, suggesting that base editor approaches to correct oncogenic mutations could be developed for functional interrogation of vulnerabilities in a personalized manner for future precision oncology applications. Significance: Repairing KRAS mutations with base editors can be used for providing a better understanding of RAS biology and may lay the foundation for improved treatments for KRAS-mutant cancers.
DNA-methyltransferase 3A (DNMT3A) mutations belong to the most frequent genetic aberrations found in adult acute myeloid leukemia (AML). Recent evidence suggests that these mutations arise early in leukemogenesis, marking leukemic progenitors and stem cells, and persist through consolidation chemotherapy, providing a pool for AML relapse. Currently, there are no therapeutic approaches directed specifically against this cell population. To unravel therapeutically actionable targets in mutant DNMT3A-driven AML cells, we have performed a focused RNAi screen in a panel of 30 primary AML samples, all carrying a DNMT3A R882 mutation. As one of the strongest hits, we identified MDM4 as a gene essential for proliferation of primary DNMT3AWT/R882X AML cells. We analyzed a publicly available RNA-Seq dataset of primary normal karyotype (NK) AML samples and found a trend towards MDM4 transcript overexpression particularly in DNMT3A-mutant samples. Moreover, we found that the MDM2/4 inhibitor ALRN-6924 impairs growth of DNMT3AWT/R882X primary cells in vitro by inducing cell cycle arrest through upregulation of p53 target genes. Our results suggest that MDM4 inhibition is a potential target in NK-AML patients bearing DNMT3A R882X mutations.
Background: Understanding the role of cancer hotspot mutations is essential for unraveling mechanisms of tumorigenesis and identifying therapeutic vulnerabilities. Correcting cancer mutations with base editing is a novel, yet promising approach for investigating the biology of driver mutations. Results: Here, we present a versatile platform to investigate the functional impact of cancer hotspot mutations through adenine base editing in combination with transcriptomic profiling. Using this approach, we correct TP53 hotspot mutations in cancer cell lines derived from diverse tissues, followed by mRNA sequencing to evaluate transcriptional changes. Remarkably, correcting these mutations not only reveals the dependency on mutant allele expression but also restores highly conserved tumor-suppressive transcriptional programs, irrespective of tissue origin or co-occurring mutations, highlighting a shared p53-dependent regulatory network. Our findings demonstrate the utility of this base editing platform to systematically interrogate the functional consequences of cancer-associated mutations and their downstream effects on gene expression. Conclusions: This work establishes a robust framework for studying the transcriptional dynamics of cancer hotspot mutations and sheds light on the conserved biological processes reinstated by p53 correction, offering potential avenues for future targeted therapies.
Despite rapid advances in precision genome editing, most clinical applications have focused on monogenic disorders. In contrast, therapeutic mutation correction in cancer has remained largely unexplored. Here, we demonstrate in vivo correction of the recurrent TP53-R273H hotspot mutation using adenine base editing in a peritoneal cancer mouse model. Liposome-mediated delivery of optimized editor mRNA and mutation-specific guide RNA achieved efficient on-target editing with minimal off-target activity in vitro and in vivo. Mutation correction restored p53 pathway function and induced significant tumor regression without observable systemic toxicity. These findings provide in vivo proof-of-concept that precise correction of recurrent cancer driver mutations is feasible and therapeutically relevant, supporting precision mutation repair as a potential therapeutic modality in solid tumors.